Lixiana Dosage/Direction for Use

Patients with Renal insufficiency: In patients with mild renal impairment (CrCL > 50 - 80 mL/min), the recommended dose is 60 mg Lixiana once daily.
In patients with moderate or severe renal impairment (CrCL 15 - 50 mL/min), the recommended dose is 30 mg Lixiana once daily.
In patients with end stage renal disease (ESRD) (CrCL < 15 mL/min) or on dialysis, the use of Edoxaban (Lixiana) is not recommended.
Patients with Hepatic insufficiency: Lixiana is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
In patients with severe hepatic impairment Edoxaban (Lixiana) is not recommended.
In patients with mild to moderate hepatic impairment the recommended dose is 60 mg Edoxaban (Lixiana) once daily. Edoxaban (Lixiana) should be used with caution in patients with mild to moderate hepatic impairment.
Elderly: No dose deduction is required.
Children and Adolescents: The safety and efficacy of Edoxaban (Lixiana) in children and adolescents less than 18 years of age have not been established. No data are available.
Patients undergoing cardioversion: Edoxaban (Lixiana) can be initiated or continued in patients who may require cardioversion. For transoesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Edoxaban (Lixiana) treatment should be started at least 2 hours before cardioversion to ensure adequate anticoagulation. Cardioversion should be performed no later than 12 hours after the dose of Edoxaban (Lixiana) on the day of the procedure.
For all patients undergoing cardioversion: Confirmation should be sought prior to cardioversion that the patient has taken Edoxaban (Lixiana) as prescribed. Decisions on initiation and duration of treatment should follow established guidelines for anticoagulant treatment in patients undergoing cardioversion.
Elderly: No dose adjustment is required since uptitration to the maximum tolerated dose is individually adjusted.
Children and Adolescents: The safety and efficacy of Edoxaban (Lixiana) in children and adolescents less than 18 years of age have not been established. No data are available.
Method of administration: For oral use.
Edoxaban (Lixiana) can be taken with or without food.